undamentalytics Newsletter

Traversa Sergio: insider trades

Chief executive at Relmada Therapeutics, Inc. 9 open-market purchases and 1 sale not made under a pre-set plan, reported from December 17, 2015 to September 11, 2026.

Would copying Traversa Sergio’s purchases have beaten the S&P 500?

Too few purchases to judge. None of their purchases has 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. After their sales, the shares moved −103.3% against the index over 12 months on average (a negative figure means selling was the right call); 100% trailed it. None of their purchases could be priced, so there is no copy portfolio.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Traversa Sergio: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 1 +74.5% +74.5% 0% 1 — — Not enough years
Sales, 12 months after the report 1 −103.3% −103.3% 100% 1 — — Not enough years
Sales, 12 months after the trade 1 −106.2% −106.2% 100% 1 — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Relmada Therapeutics, Inc. RLMD Chief Executive Officer91December 17, 2015September 11, 2026

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
September 11, 2026September 9, 2026 RLMD Purchase $828,000 not yetnot yetnot yet
December 16, 2025December 15, 2025 RLMD Purchase $113,300 not yetnot yetnot yet
November 6, 2025November 5, 2025 RLMD Purchase $599,500 not yetnot yetnot yet
August 28, 2025August 26, 2025 RLMD Purchase $178,095 not yetnot yetnot yet
May 20, 2025May 16, 2025 RLMD Purchase $175,245 not yetnot yetnot yet
September 11, 2024September 9, 2024 RLMD Purchase $395,115 not yetnot yetnot yet
January 31, 2024January 29, 2024 RLMD Purchase $386,753 not yetnot yetnot yet
December 12, 2022December 8, 2022 RLMD Purchase $116,025 not yetnot yetnot yet
July 5, 2022June 30, 2022 RLMD Sale $559,577 +74.5%−103.3%−106.2%
December 17, 2015December 15, 2015 RLMD Purchase $57,792 not yetnot yetnot yet

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Traversa Sergio traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.